Back to search

Finland· FI-REL-REL24848

Promeris (Pieni Kissa)

A metaflumizone product containing metaflumizonum, registered in Finland by Pfizer Ltd.

ATC QP53AX25

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedPromeris (Pieni Kissa)ATCQP53AX25REGISTER NO.FI-REL-REL24848PACKS LISTED0CHECKEDSeptember 27, 2026

The record

At a glance

Fimea (Finland)
Active substance
Metaflumizonum
Manufacturer
Pfizer Ltd
Country
Finland (FI)
ATC code
QP53AX25
ATC class
Metaflumizone
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same class

Other records under QP53AX25

Metaflumizone, as other registers publish it.

All metaflumizonum products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/303a904f-e807-4cb5-80d8-99caeefa635e
GET /v1/drugs/303a904f-e807-4cb5-80d8-99caeefa635e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": null,
  "form": "kertavaleluliuos",
  "route": "Topical",
  "ddd_unit": null,
  "strength": "160 mg",
  "atc_label": "Metaflumizone",
  "ma_number": null,
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": "EU/2/06/064/001-002",
  "fimea_rel_id": "REL24848",
  "authorised_at": "2006-12-19"
}

See everything about metaflumizonum.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.